| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | - |
| Drug | Dexamethasone Intravitreal Implant |
| Brand | Ozurdex® |
| Indication | Treatment of macular oedema following Retinal Vein Occlusion |
| Assessment Process | |
| Rapid review commissioned | 12/11/2010 |
| Rapid review completed | 16/12/2010 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full pharmacoeconomic assessment commissioned by HSE | 24/11/2011 |
| NCPE assessment completed | 16/03/2012 |
| NCPE assessment outcome | Reimbursement not recommended the submitted price, Ozurdex® cannot be considered cost-effective therapy for the treatment of macular oedema following retinal vein occlusion |
July 2013
Following resubmission of pricing information the NCPE conclude that Ozurdex® is a cost effective treatment strategy versus observation (base case) in RVO. The ICER for Ozurdex® versus observation is €25,601/QALY (basecase). The probability of cost effectiveness at a threshold of €45,000/QALY is 88.97%.